SCHEMBL277765

SCHEMBL277765

CCC(C(N)=O)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.43
CA2 P00918 5/20 0.43
CA7 P43166 3/20 0.39
CA14 Q9ULX7 3/20 0.39
TSHR P16473 1/20 0.38
LMNA P02545 2/20 0.31
HSD17B10 Q99714 1/20 0.31
ALOX15 P16050 1/20 0.31
CA12 O43570 2/20 0.31
CA9 Q16790 2/20 0.31
DPP4 P27487 1/20 0.31
CA3 P07451 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA13 Q8N1Q1 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8526815 1.00 CA1 (0.43) CA1CA2CA7CA14TSHR
SCHEMBL29920805 0.82 CA1 (0.41) CA1CA2CA7CA14TSHR
SCHEMBL28876492 0.80 CA1 (0.40) CA1CA2CA7CA14TSHR
SCHEMBL21575128 0.80 CA2 (0.45) CA1CA2CA7CA14TSHR
SCHEMBL21992098 0.80 CA1 (0.40) CA1CA2CA7CA14
SCHEMBL14453098 0.80 CA2 (0.45) CA1CA2CA7CA14TSHR
SCHEMBL15672774 0.80 CA1 (0.40) CA1CA2CA7CA14
SCHEMBL13583496 0.78 CA1 (0.39) CA1CA2
SCHEMBL5266419 0.78 CA1 (0.39) CA1CA2EPHX1
SCHEMBL14534529 0.77 CA1 (0.37) CA1CA2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190125701-A1 Compositions and Methods for Treating Viral Infection in Mammals UNIV YALE (US) 2019-05-02 US claimed
EP-3452172-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS Yale University (US) 2019-03-13 EP claimed
WO-2017192799-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS YALE UNIVERSITY (US) 2017-11-09 WO claimed
US-11174271-B2 6-membered uracil isosteres CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-16 US disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 US disclosed
US-20190125701-A1 Compositions and Methods for Treating Viral Infection in Mammals UNIV YALE (US) 2019-05-02 US disclosed
US-20190125701-A1 Compositions and Methods for Treating Viral Infection in Mammals UNIV YALE (US) 2019-05-02 US disclosed
EP-3452172-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS Yale University (US) 2019-03-13 EP disclosed
WO-2019036679-A1 COMPOSITIONS COMPRISING AROMATIC COMPOUNDS FOR USE IN OIL AND/OR GAS WELLS AND RELATED METHODS FLOTEK CHEMISTRY, LLC (US) 2019-02-21 WO disclosed
CN-108431135-A The manufacturing method of resin combination, the manufacturing method of resin, the manufacturing method of resin film and electronic equipment 东丽株式会社 2018-08-21 CN disclosed
WO-2017192799-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS YALE UNIVERSITY (US) 2017-11-09 WO disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed
CN-1501794-A Cooling composition 2004-06-02 CN disclosed
EP-0847988-B1 Process for the preparation of N-hydrocarbyl-substituted amides LUBRIZOL CORP (US) 2003-09-03 EP disclosed
WO-2000000499-A1 METHOD FOR PREPARING OLIGONUCLEOTIDES WITH BORANOPHOSPHATE LINKAGES ISIS PHARMACEUTICALS, INC. (US) 2000-01-06 WO disclosed
EP-0847988-A1 Process for the preparation of N-hydrocarbyl-substituted amides The Lubrizol Corporation (US) 1998-06-17 EP disclosed
US-5712413-A Process for the preparation of N-hydrocarbyl-substituted amides such as tert-butylacrylamide via the Ritter reaction using solid heteropolyacid catalysts THE LUBRIZOL CORPORATION (US) 1998-01-27 US disclosed
CN-1084387-A Coolant compositions PROCTER & GAMBLE (US) 1994-03-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 CA1 2516/4885CA2 2631/4885CA7 3539/4885
US-11174271-B2 6-membered uracil isosteres UNG, DUT, DPYD CA1 3556/4885CA2 4284/4885CA7 2711/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD CA1 3556/4885CA2 4284/4885CA7 2711/4885
US-20190125701-A1 Compositions and Methods for Treating Viral Infection in Mammals RPL35, PIGS, HAVCR2 CA1 334/4885CA2 718/4885CA7 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.